SpringerProtocols: Abstract: 12. Engineering Multivalent Antibody Fragments for In Vivo Targeting

12. Engineering Multivalent Antibody Fragments for In Vivo Targeting

By: Anna M. Wu²

Abstract

Full Text

Download PDF (315K)

Antibodies, especially in the genetically engineered form, provide a powerful and diverse set of reagents for the recognition of biological structures. Of key importance to those in the antibody field are advances in genomics and proteomics, fostered by technology such as gene-expression profiling, protein microarrays, and high-throughput validation assays, which are providing a multitude of new protein targets for investigation. In parallel, antibody technologies such as phage display (Chapter 8) and ribosome display (Chapter 9), are providing agents to specifically recognize these novel targets, with broad future applications in detection and intervention in fields as diverse as human health, agriculture, and the environment.

Affiliation(s): (2) Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA

Book Title: Antibody Engineering: Methods and Protocols

Series: Methods in Molecular Biology | Volume: 248 | Pub. Date: Dec-05-2003 | Page Range: 209-225 | DOI: 10.1385/1-59259-666-5:209

Subject: Biochemistry

References

Download References

1.	Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S. M., et al. (1988) Single-chain antigen-binding proteins. Science 242, 423–426.

2.	Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotny, J., Margolies, M. N., et al. (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85, 5879–5883.

3.	Desplancq, D., King, D. J., Lawson, A.D.G., and Mountain, A. (1994) Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3. Protein Eng. 7, 1027–1033.

4.	Huston, J. S., George, A.J.T., Adams, G. P., Stafford, W. F., Jamar, F., Tsai, M.-S., et al. (1996) Single-chain Fv radioimmunotargeting. Quarterly Journal of Nuclear Medicine 40, 320–323.

5.	Wu, A. M. and Yazaki, P. J. (2000) Designer genes: recombinant antibody fragments for biological imaging. Quarterly Journal of Nuclear Medicine 44, 268–283.

6.	Yokota, T., Milenic, D. E., Whitlow, M., and Schlom, J. (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52, 3402–3408.

7.	Begent, R.H.J., Verhaar, M. J., Chester, K. A., Casey, J. L., Green, A. J., Napier, M. P., et al. (1996) Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med. 2, 979–984.

8.	Mayer, A., Tsiompanou, E., O’Malley, D., Boxer, G. M., Bhatia, J., Flynn, A. A., et al. (2000) Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin. Cancer Res. 6, 1711–1719.

9.	Larson, S. M., El-Shirbiny, A. M., Divgi, C. R., Sgouros, G., Finn, R. D., Tschmelitsch, J., et al. (1997) Single chain antigen binding protein (sFv CC49)—First human studies in colorectal carcinoma metastatic to liver. Cancer 80 (Suppl.) 2458–2468.

10.	Whitlow, M., Bell, B. A., Feng, S.-L., Filpula, D., Hardman, K. D., Hubert, S. L., et al. (1993) An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng. 6, 989–995.

11.	Holliger, P., Prospero, T., and Winter, G. (1993) Diabodies: small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90, 6444–6448.

12.	Peresic, O., Webb, P. A., Holliger, P., Winter, G., and Williams, R. L. (1994) Crystal structure of a diabody, a bivalent antibody fragment. Structure 2, 1217–1226.

13.	Adams, G. P., McCartney, J. E., Tai, M.-S., Oppermann, H., Huston, J. S., Stafford, W. F., et al. (1993) Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 53, 4026–4034.

14.	Wu, A. M., Chen, W., Raubitschek, A. A., Williams, L. E., Fischer, R., Hu, S.-Z., et al. (1996) Tumor localization of anti-CEA single chain Fvs: Improved targeting by non-covalent dimers. Immunotechnology 2, 21–36.

15.	Wu, A. M., Williams, L. E., Zieran, L., Padma, A., Sherman, M. A., Bebb, G. G., et al. (1999) Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumor Targeting 4, 47–58.

16.	Adams, G. P., Schier, R., McCall, A. M., Crawford, R. S., Wolf, E. J., Weiner, L. M., and Marks, J. D. (1998) Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer 77, 1405–1412.

17.	Viti, F., Tarli, L., Giovannoni, L., Zardi, L., and Neri, D. (1999) Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 59, 347–352.

18.	Pack, P. and Pluckthun, A. (1992) Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with avidity in Escherichia coli. Biochemistry 31, 1579–1584.

19.	Hu, S.-z., Shively, L., Raubitschek, A. A., Sherman, M., Williams, L. E., Wong, J.Y.C., et al. (1996) Minibody: a novel engineered anti-CEA antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56, 3055–3061.

20.	Li, E., Pedraza, A., Bestagno, M., Mancardi, S., Sanchez, R., and Burrone, O. (1997) Mammalian cell expression of dimeric small immune proteins (SIP). Protein Eng. 10, 731–736.

21.	De Kruif, J. and Logtenberg, T. (1996) Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J. Biol. Chem. 271, 7630–7634.

22.	McGregor, D. P., Molloy, P. E., Cunningham, C., and Harris, W. J. (1994) Spontaneous assembly of bivalent single chain antibody fragments in Escherichia coli. Mol. Immunol. 31, 219–226.

23.	Wu, A. M., Yazaki, P. J., Tsai, S., Nguyen, K., Anderson, A. L., McCarthy, D. W., et al. (2000) High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment.PG. Proc. Natl. Acad. Sci. USA 97, 8495–8500.

24.	Ghetie, V. and Ward, E. S. (1997) FcRn: the MHC class I-related receptor that is more than an IgG transporter, in Immunology Today, Vol. 18, pp. 592–598.

25.	Slavin-Chiorini, D. C., Kashmiri, S.V.S., Schlom, J., Calvo, B., Shu, L. M., Schott, M. E., et al. (1995) Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res. 55, (Suppl.) 5957s–5967s.

26.	Iliades, P., Kortt, A. A., and Hudson, P. J. (1997) Triabodies: single chain Fv fragments without a linker form trivalent trimers. FEBS Lett. 409, 437–441.

27.	Le Gall, F., Kipriyanov, S. M., Moldenhauer, G., and Little, M. (1999) Di-, tri-and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett. 453, 164–168.

28.	Dolezal, O., Pearce, L. A., Lawrence, L. J., McCoy, A. J., Hudson, P. J., and Kortt, A. A., et al. (2000) ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in VL to VH orientation drives the formation of dimers, trimers, tetramers, and higher molecular mass multimers. Protein Eng. 13, 565–574.

29.	Atwell, J. L., Breheney, K. A., Lawrence, L. J., McCoy, A. J., Kortt, A. A., and Hudson, P. J. (1999) scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng. 12, 597–604.

30.	Hudson, P. J. and Kortt, A. A. (1999) High avidity scFv multimers: diabodies and triabodies. J. Immunol. Methods. 231, 177–190.

31.	Pei, X. Y., Holliger, P., Murzin, A. G., and Williams, R. L. (1997) The 2.0-Å resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows are arrangement of VH CDR3. Proc. Natl. Acad. Sci. USA 94, 9637–9642.

32.	Kipriyanov, S. M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., Von der Lieth, C. W., Matys, E. R., et al. (1999) Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol. 293, 41–56.

33.	Goel, A., Colcher, D., Baranowska-Kortylewicz, J., Augustine, S., Booth, B. J., Pavlinkova, G., et al. (2000) Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res. 60, 6964–6971.

34.	Singh, R. K., Joshi, V. K., Goel, R. K., Gambhir, S. S., and Acharya, S. B. (1996) Pharmacological actions of Pongamia pinnata seeds—a preliminary study. Indian J. Exp. Biol. 34, 1204–1207.

35.	Pack, P., Müller, K., Zahn, R., and Plückthun, A. (1995) Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J. Mol. Biol. 246, 28–34.

36.	Willuda, J., Kubetzko, S., Waibel, R., Schubiger, P. A., Zangemeister-Wittke, U., and Pluckthun, A. (2001) Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides. J. Biol. Chem. 276, 14,385–14,392.

37.	Santos, A. D., Kashmiri, S. V., Hand, P. H., Schlom, J., and Padlan, E. A. (1999) Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody. Clin. Cancer Res. 5, 3118s–3123s.

38.	Alt, M., Müller, R., and Kontermann, R. E. (1999) Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gammal Fc or CH3 region. FEBS Lett. 454, 90–94.

39.	Dübel, S., Breitling, F., Kontermann, R., Schmidt, T., Skerra, A., and Little, M. (1995) Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv). J. Immunol. Methods 178, 201–209.

40.	Goshorn, S., Sanderson, J., Axworthy, D., Lin, Y., Hylarides, M., and Schultz, J. (2001) Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy. Cancer Biother. Radiopharm.

41.	Goel, A., Baranowska-Kortylewicz, J., Hinrichs, S. H., Wisecarver, J., Pavlinkova, G., Augustine, S., et al. (2001) 99mTc-labeled divalent and tetravalent CC49 single-chain Fv’s: novel imaging agents for rapid in vivo localization of human colon carcinoma. J. Nucl. Med. 42, 1519–1527.

42.	Dübel, S., Breitling, F., Fuchs, P., Zewe, M., Gotter, S., Welschof, M., et al. (1994) Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers. J. Immunol. Methods 175, 89–95.

43.	Wu, A. M., Tan, G. J., Sherman, M. A., Clarke, P., Olafsen, T., Forman, S. J., et al. (2001) Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng. 14, 1025–1033.

44.	Volkel, T., Korn, T., Bach, M., Muller, R., and Kontermann, R. E. (2001) Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies. Protein Eng. 14, 815–823.

Comments (Loading...)

Post comment/View all comments